Literature DB >> 23535156

Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model.

Smadar Gertel-Lapter1, Keren Mizrachi, Sonia Berrih-Aknin, Sara Fuchs, Miriam C Souroujon.   

Abstract

Myasthenia gravis (MG) is an antibody mediated, T cell dependent autoimmune disease characterized by muscle fatigability in which autoantibodies directed to the acetylcholine receptor (AChR) impair neuromuscular transmission. The identification of CD4⁺CD25⁺Foxp3Treg cells as important regulators of tolerance opened a major area of investigation raising the possibility that a dysfunction in the Treg compartment is involved in the etiology and pathogenesis of autoimmune diseases, including MG. In this paper we summarize shortly Treg abnormalities that were reported in MG patients and report on our studies of Treg in experimental autoimmune MG (EAMG). Hopefully these studies would pave the way towards the development of novel Treg-based treatment modalities that will restore self-tolerance in MG and other autoimmune diseases. In our previous studies in EAMG we have shown that Treg cells transferred from healthy rat donors to myasthenic rats suppress EAMG. However, Treg cells from sick animals do not have the same in vivo suppressive activity as those from healthy donors. The objective of the present study was to further characterize quantitative and qualitative alterations in Treg cells of rats with EAMG. We found that the frequency of CD4⁺CD25⁺Foxp3Treg cells within the spleen and PBL was decreased in EAMG rats as compared to naïve and CFA-immunized healthy controls. Treg cells from myasthenic rats were less effective than Treg cells from controls in suppressing the proliferation of CD4⁺T effector cells in response to ConA and of B cells in response to LPS. Moreover, CD4⁺CD25⁺ cells from EAMG rats exhibited an elevated extent of apoptosis and expressed upregulated levels of FAS and of Th17-associated cytokines. Since EAMG is an induced disease, these quantitative and qualitative alterations in Treg cells do not reflect predisposing impairments and seem to be associated with the specific autoimmune response resulting from AChR immunization.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23535156     DOI: 10.1016/j.autrev.2013.03.009

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  15 in total

Review 1.  Microfluidic devices for disease modeling in muscle tissue.

Authors:  Mollie M Smoak; Hannah A Pearce; Antonios G Mikos
Journal:  Biomaterials       Date:  2018-08-30       Impact factor: 12.479

Review 2.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

3.  Analysis of serum miRNA profiles of myasthenia gravis patients.

Authors:  Gisela Nogales-Gadea; Alba Ramos-Fransi; Xavier Suárez-Calvet; Miquel Navas; Ricard Rojas-García; Jose Luis Mosquera; Jordi Díaz-Manera; Luis Querol; Eduard Gallardo; Isabel Illa
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

4.  Deficits in endogenous adenosine formation by ecto-5'-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis.

Authors:  Laura Oliveira; Alexandra Correia; Ana Cristina Costa; Sónia Guerra-Gomes; Fátima Ferreirinha; Maria Teresa Magalhães-Cardoso; Manuel Vilanova; Paulo Correia-de-Sá
Journal:  Mediators Inflamm       Date:  2015-01-27       Impact factor: 4.711

5.  Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus.

Authors:  Tina Hennerici; Robert Pollmann; Thomas Schmidt; Maria Seipelt; Björn Tackenberg; Christian Möbs; Kamran Ghoreschi; Michael Hertl; Rüdiger Eming
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

6.  Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis.

Authors:  Ailian Du; Shiqian Huang; Xiaonan Zhao; Kuan Feng; Shuangyan Zhang; Jiefang Huang; Xiang Miao; Fulvio Baggi; Rennolds S Ostrom; Yanyun Zhang; Xiangjun Chen; Congfeng Xu
Journal:  Autophagy       Date:  2017-09-29       Impact factor: 16.016

Review 7.  Regulatory T cells in multiple sclerosis and myasthenia gravis.

Authors:  K M Danikowski; S Jayaraman; B S Prabhakar
Journal:  J Neuroinflammation       Date:  2017-06-09       Impact factor: 8.322

8.  Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats.

Authors:  Alessandra Consonni; Chiara Cordiglieri; Elena Rinaldi; Roberta Marolda; Ilaria Ravanelli; Elena Guidesi; Marina Elli; Renato Mantegazza; Fulvio Baggi
Journal:  Oncotarget       Date:  2018-04-27

9.  A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.

Authors:  Alessandra Consonni; Sapna Sharma; Karin Schön; Cristina Lebrero-Fernández; Elena Rinaldi; Nils Yngve Lycke; Fulvio Baggi
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

10.  The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the development of autoimmune myasthenia gravis.

Authors:  Mohamed Nasreldin Thabit Hamdoon; Mona Fattouh; Asmaa Nasr El-Din; Hassan M Elnady
Journal:  Electron Physician       Date:  2016-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.